Molecular Biology

, Volume 37, Issue 6, pp 836–840 | Cite as

Methylation Profile of Several Tumor Suppressor Genes in Non-Small-Cell Lung Cancer

  • V. V. Zemlyakova
  • A. I. Zhevlova
  • I. B. Zborovskaya
  • V. V. Strelnikov
  • K. K. Laktionov
  • D. V. Zaletaev
  • M. V. Nemtsova


Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, HIC1, and N33 5′ regions in non-small cell lung cancer (51 tumors). Methylation was observed for the two suppressor genes involved in controlling the cell cycle through the Cdk–Rb–E2F signaling pathway, RB1 (10/51, 19%) and p16 (20/51, 39%). The highest methylation frequencies were established for CDH1 (72%) and HIC1 (82%). The CpG islands of p14 and p15 proved to be nonmethylated. At least one gene was methylated in 90% (46/51) tumors and no gene, in 10% (5/51) tumors. In addition, the genes were tested for methylation in peripheral blood lymphocytes of healthy subjects. Methylation frequency significantly differed between tumors and normal cells in the case of RB1, p16, CDH1, HIC1, and N33. Gene methylation frequency was tested for association with histological type of the tumor and stage of tumor progression. Methylation index of a panel of tumor suppressor genes was established for groups of tumors varying in clinical and morphological parameters.

non-small-cell lung cancer RB1 p16/CDKN2A p15/CDKN2B p14/ARF CDH1 HIC1 N33 methylation CpG island methylation-sensitive PCR 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zaletaev D.V. 2000. DNA diagnostics in oncology. Mol. Bio l 34, 671–683.Google Scholar
  2. 2.
    Nemtsova M.V., Zemlyakova V.V., Zhevlova A.I., et al. 2002. Methylation profile of tumor suppressor genes in various malignancies. Vestn. Inst. Mol. Med. MMA im. I.M. Sechenova. 2, 65–84.Google Scholar
  3. 3.
    Kim D.H., Nelson H.H., Wiencke J.K. et al. 2001. p16(INK4a) and histology-specific methylation of CpG island by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 61, 3419–3424.Google Scholar
  4. 4.
    Zochbauer-Muller S., Kwung M.F., Virmani A.K. et al. 2001. Aberrant promoter methylation of multiple genes in non-small cell lung cancer. Cancer Res. 61, 249–255.Google Scholar
  5. 5.
    Bian J., Wang Y., Kim H. et al. 1996. Suppression of in vitro tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases-3 (TIMP-3). Carcinogenesis 17, 1805–1811.Google Scholar
  6. 6.
    Houle B., Rochette-Egly C., Bradley W. et al. 1993. Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. USA. 90, 985–989.Google Scholar
  7. 7.
    Zochbauer-Muller S., Minna J., Gazdar A. 2002. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist. 7, 451–457.Google Scholar
  8. 8.
    Esteller M., Corn P.G., Baylin S.B. et al. 2001. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225–3229.Google Scholar
  9. 9.
    Zemlyakova V.V., Zhevlova, A.I., Strelnikov, V.V., et al. 2003. Abnormal methylation of several tumor suppressor genes in sporadic breast cancer. Mol. Bio l 37, 696–703.Google Scholar
  10. 10.
    Rathi A., Virmani A.K., Schorge J.O. et al. 2002. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin. Cancer Res. 8, 3324–3331.Google Scholar
  11. 11.
    Virmani A.K., Muller C., Rathi A. et al. 2001. Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res. 7, 584–589.Google Scholar
  12. 12.
    Virmani A.K., Tsou J.A., Siegmound K.D. et al. 2002. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol. Biomarkers Prevention. 11, 291–297.Google Scholar
  13. 13.
    Lee S., Kim W.H., Jung H.Y. et al. 2002. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Amer. J. Pathol. 1, 1015–1021.Google Scholar
  14. 14.
    Sambrook J., Fritsh E.F., Maniatis T. 1989. Molecular cloning: a laboratory manual. 2nd end. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.Google Scholar
  15. 15.
    Strelnikov V.V., Nemtsova M.V., Chesnokova G.G. et al. 1999. Diagnostics of Martin-Bell syndrome by structural and functional changes in the 5'-untranslated region of the FMR1 gene. Mol. Bio l 33, 330–336.Google Scholar
  16. 16.
    Babenko O.V., Zemlyakova V.V., Saakyan S.V., et al. 2002. RB1 and CDKN2A functional defects resulting in retinoblastoma. Mol. Bio l 36, 777–783.Google Scholar
  17. 17.
    Baur A.S., Shaw P., Burri N. et al. 1999. Frequent methylation silencing of p15 INK4B (MTSI) and p16 INK4A (MTSI) in B-cell and T-cell lymphomas. Blood. 94, 1773–1781.Google Scholar
  18. 18.
    Graff J.R., Herman J.R., Myohanen S. et al. 1997. Map-ping patterns of CpG island methylation in normal and neoplastic cells implicated both upstream and down-stream region in de novo methylation. J. Biol. Chem. 227, 22322–22329.Google Scholar
  19. 19.
    Konishi N., Nakamura M., Kishi M. et al. 2002. DNA hypermethylation status of multiple genes in prostate adenocarcinomas. Jpn. J. Can. Res. 93, 767–773.Google Scholar
  20. 20.
    Fujii H., Biel M.A., Zhou W. et al. 1998. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene. 16, 2159–2164.Google Scholar
  21. 21.
    Li Q., Jedlicka A., Ahuja N. et al. 1998. Concordant methylation of the ER and N33 genes in glioblastoma multiform. Oncogene. 16, 3197–3202.Google Scholar
  22. 22.
    Weintraub S. 1996. Inactivation of tumor suppressor proteins in lung cancer. Am. J. Respir. Cell Mol. 15, 150–155.Google Scholar
  23. 23.
    Belinsky S.A., Nikula K.J., Palmisano W.A. et al. 1998. Aberrant methylation of p16 (INK4α) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA. 95, 11891–11896.Google Scholar
  24. 24.
    Brabender J., Usabel H., Danenberg K.D. et al. 2001. APC gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene. 20, 3528–3532.Google Scholar
  25. 25.
    Burbee D.C., Forgacs E., Zochbauer-Muller S. et al. 2001. Epigenetic inactivation of RASSF1A in lung and breast cancer and malignant phenotipe suppression. Natl. Cancer Inst. 93, 691–699.Google Scholar
  26. 26.
    Tang X., Khuri F.R., Lee J.J. et al. 2000. Hypermethylation of the death-associated protein (DAP) kinase promoter and agressiveness in stage I non-small cell lung cancer. J. Natl. Cancer Inst. 92, 1511–1516.Google Scholar
  27. 27.
    Palmissano W.A., Divine K.K., Saccomanno G. et al. 2000, Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954–5958.Google Scholar
  28. 28.
    Zborovskaya I.B., Chizhikov V.V. 2003. Detection of molecular defects in lung cancer: The possibilities of clinical use. Novoe v terapii raka legkogo (New Findings in Therapy of Lung Cancer). Perevodchikova N.I., Ed. Moscow: Ross. Onkol. Nauchn. Tsentr im. Blokhina, 16–40.Google Scholar

Copyright information

© MAIK “Nauka/Interperiodica” 2003

Authors and Affiliations

  • V. V. Zemlyakova
    • 1
  • A. I. Zhevlova
    • 1
  • I. B. Zborovskaya
    • 2
  • V. V. Strelnikov
    • 3
  • K. K. Laktionov
    • 2
  • D. V. Zaletaev
    • 1
    • 3
  • M. V. Nemtsova
    • 1
  1. 1.Research Center for Medical GeneticsRussian Academy of Medical SciencesMoscowRussia
  2. 2.Institute of Carcinogenesis, Blokhin Cancer Research CenterRussian Academy of Medical SciencesMoscowRussia
  3. 3.Institute of Molecular Medicine, Sechenov Medical AcademyMinistry of Health of the Russian FederationMoscowRussia

Personalised recommendations